CN107029227A - 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途 - Google Patents

热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途 Download PDF

Info

Publication number
CN107029227A
CN107029227A CN201710040168.9A CN201710040168A CN107029227A CN 107029227 A CN107029227 A CN 107029227A CN 201710040168 A CN201710040168 A CN 201710040168A CN 107029227 A CN107029227 A CN 107029227A
Authority
CN
China
Prior art keywords
ser
leu
lys
thr
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710040168.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·M·德哈恩
P·J·M·罗特尔
B·J·海捷玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mucosis BV
Original Assignee
Mucosis BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosis BV filed Critical Mucosis BV
Publication of CN107029227A publication Critical patent/CN107029227A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201710040168.9A 2013-03-14 2014-03-12 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途 Pending CN107029227A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/828,667 US9060975B2 (en) 2013-03-14 2013-03-14 Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US13/828,667 2013-03-14
CN201480022815.8A CN105246910A (zh) 2013-03-14 2014-03-12 热稳定的呼吸道合胞病毒融合前f蛋白寡聚物及其在免疫组合物中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480022815.8A Division CN105246910A (zh) 2013-03-14 2014-03-12 热稳定的呼吸道合胞病毒融合前f蛋白寡聚物及其在免疫组合物中的用途

Publications (1)

Publication Number Publication Date
CN107029227A true CN107029227A (zh) 2017-08-11

Family

ID=50241453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710040168.9A Pending CN107029227A (zh) 2013-03-14 2014-03-12 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途
CN201480022815.8A Pending CN105246910A (zh) 2013-03-14 2014-03-12 热稳定的呼吸道合胞病毒融合前f蛋白寡聚物及其在免疫组合物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480022815.8A Pending CN105246910A (zh) 2013-03-14 2014-03-12 热稳定的呼吸道合胞病毒融合前f蛋白寡聚物及其在免疫组合物中的用途

Country Status (8)

Country Link
US (2) US9060975B2 (enExample)
EP (2) EP2970393B1 (enExample)
JP (1) JP6285469B2 (enExample)
CN (2) CN107029227A (enExample)
AU (1) AU2014230822B2 (enExample)
BR (1) BR112015022617A2 (enExample)
CA (1) CA2905571A1 (enExample)
WO (1) WO2014140083A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684747A (zh) * 2018-07-06 2020-01-14 厦门大学 灭活及保存呼吸道合胞病毒的方法
CN112480217A (zh) * 2020-11-30 2021-03-12 广州市锐博生物科技有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CN113227123A (zh) * 2018-11-01 2021-08-06 Sk生物科学株式会社 重组呼吸道合胞病毒f蛋白以及包含该蛋白的疫苗组合物
CN114957407A (zh) * 2019-04-02 2022-08-30 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
WO2024192698A1 (zh) * 2023-03-22 2024-09-26 中科牧维(南京)生物科技有限公司 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014212268B2 (en) 2013-02-01 2018-07-19 Medimmune, Llc Respiratory Syncytial Virus F protein epitopes
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
WO2017075125A1 (en) * 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
EP3439672B1 (en) * 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
IL264119B2 (en) * 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
CN113832116B (zh) * 2017-01-12 2024-09-13 厦门大学 稳定呼吸道合胞病毒融合蛋白的方法
PL3601367T3 (pl) 2017-03-30 2025-03-31 The University Of Queensland Cząsteczki chimeryczne i ich zastosowania
AU2018249533C1 (en) 2017-04-04 2023-10-12 Institute For Research In Biomedicine Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
CN109694400A (zh) * 2019-01-31 2019-04-30 苏州高泓利康生物科技有限公司 一种表达呼吸道合胞病毒f蛋白及其制备方法
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
EP4141121A4 (en) * 2020-04-22 2024-07-10 POSTECH Research and Business Development Foundation RECOMBINANT HEMAGGLUTININ PROTEIN DERIVED FROM TRIMER-FORMING INFLUENZA VIRUS SURFACE PROTEIN AND USE THEREOF
CA3179246A1 (en) * 2020-05-19 2021-11-25 Yves Durocher Use of resistin as a trimerization partner for expression of trimeric proteins
KR20250140099A (ko) * 2023-02-03 2025-09-24 노바백스, 인코포레이티드 Rsv f 백신 제형
WO2024251281A1 (zh) * 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
US12383614B2 (en) 2023-12-21 2025-08-12 Yikang Biotech (Suzhou) Co., Ltd. Mutants of respiratory syncytial virus fusion proteins
CN117886902B (zh) * 2023-12-21 2024-11-26 易康生物(苏州)有限公司 改良的呼吸道合胞病毒融合f蛋白突变体及其应用
CN120329390A (zh) * 2025-03-03 2025-07-18 中国医学科学院医学生物学研究所 基于异源三聚体基序的蛋白的改造及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149743A2 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
US20120070446A1 (en) * 2009-10-06 2012-03-22 Aimm Therapeutics B.V. Rsv specific binding molecule
WO2012128628A1 (en) * 2011-03-22 2012-09-27 Mucosis B.V. Immunogenic compositions in particulate form and methods for producing the same
WO2012158613A1 (en) * 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916726A1 (en) 1997-11-13 1999-05-19 Rijksuniversiteit te Groningen Attaching substances to micro-organisms
CA2450318C (en) 2001-06-11 2011-08-02 Applied Nanosystems B.V. Improved methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2010149745A1 (en) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
EP4218799A1 (en) * 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149743A2 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
US20120070446A1 (en) * 2009-10-06 2012-03-22 Aimm Therapeutics B.V. Rsv specific binding molecule
WO2012128628A1 (en) * 2011-03-22 2012-09-27 Mucosis B.V. Immunogenic compositions in particulate form and methods for producing the same
WO2012158613A1 (en) * 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALAN RIGTER等: "A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles", 《PLOS ONE》 *
IVY WIDJAJA等: "Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics", 《PLOS ONE》 *
M. BEGONA RUIZ-ARGUELLO等: "Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism", 《JOURNAL OF GENERAL VIROLOGY》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684747A (zh) * 2018-07-06 2020-01-14 厦门大学 灭活及保存呼吸道合胞病毒的方法
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
CN113227123A (zh) * 2018-11-01 2021-08-06 Sk生物科学株式会社 重组呼吸道合胞病毒f蛋白以及包含该蛋白的疫苗组合物
CN114957407A (zh) * 2019-04-02 2022-08-30 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
US12454553B2 (en) 2019-04-02 2025-10-28 Sanofi Antigenic multimeric respiratory syncytial virus polypeptides
CN112480217A (zh) * 2020-11-30 2021-03-12 广州市锐博生物科技有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
WO2024192698A1 (zh) * 2023-03-22 2024-09-26 中科牧维(南京)生物科技有限公司 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂

Also Published As

Publication number Publication date
JP2016510983A (ja) 2016-04-14
US20140271696A1 (en) 2014-09-18
EP2970393A1 (en) 2016-01-20
AU2014230822B2 (en) 2018-04-12
WO2014140083A1 (en) 2014-09-18
JP6285469B2 (ja) 2018-02-28
US9060975B2 (en) 2015-06-23
EP2970393B1 (en) 2017-01-11
CA2905571A1 (en) 2014-09-18
USRE47471E1 (en) 2019-07-02
CN105246910A (zh) 2016-01-13
BR112015022617A2 (pt) 2017-10-31
AU2014230822A1 (en) 2015-10-01
EP3178840A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
CN107029227A (zh) 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途
CN113292640B (zh) 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
JP6469081B2 (ja) 安定化された可溶性融合前ｒｓｖｆポリペプチド
JP2016522230A (ja) 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
MD3439672T2 (ro) Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV
US20240189416A1 (en) Stabilized coronavirus spike protein fusion proteins
CN114478718B (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CN118772250B (zh) 一种rsv f蛋白突变体及其制法与应用
JP2024502823A (ja) 安定なコロナウィルスタンパク質およびそのワクチン組成物
CN109851678A (zh) 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
WO2023138333A1 (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CN116745408A (zh) 稳定的冠状病毒刺突蛋白融合蛋白
WO2025200576A1 (zh) 重组rsv f蛋白及其用途
HK40073047B (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
Lee et al. Mosaic receptor-binding domain nanoparticles induce protective immunity against SARS-CoV-2 challenges
HK40073047A (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
HK40073048A (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
HK40067420B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40067420A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40073046A (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
HK40073046B (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
HK40054535B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40054535A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170811